Eli Lilly’s stock soars as successful trial of weight-loss pill is a game changer - MarketWatch
1. LLY stock surged 11% after positive Phase 3 trial results. 2. Orforglipron shows significant diabetes and obesity treatment potential. 3. First oral GLP-1 medicine to complete Phase 3, enhancing market competitiveness. 4. Expected regulatory submission by year-end may boost future sales. 5. Ongoing investor interest in obesity drugs will benefit LLY's stock.